EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Whole exome germline sequencing in early‐onset prostate cancer patients: Genomic findings and clinical outcomes

Nava Siegelmann-Danieli iD, Victoria Neiman, Avital Bareket-Samish, Racheli Berger, Asaf Peretz, Hillel Alapi, Erez Tsur, Tal Patalon, Daniella Beller, Galit Rimler, Gabriel Chodick, Mordechai Shohat

The Prostate · 2024

DOI: 10.1002/pros.24622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Nava Siegelmann-Danieli und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Exome, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: KSM Maccabi Healthcare Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whole exome sequencing (WES) furthered our understanding of various tumors. We assessed the occurrence of germline likely pathogenic/pathogenic (LP/P) variants, disease features, and clinical outcomes in early‐onset prostate cancer.

Methods

This retrospective study ( N = 134) included consecutive prostate cancer patients who donated blood samples for research purposes to the Kahn‐Sagol‐Maccabi biobank. Patients diagnosed at >65 years were excluded. Clinical characteristics were extracted from the medical records. Germline WES was performed with analysis reporting on oncogenetic, two immunogenic, and a secondary minimum list panels (121, 468, 76, and 59 genes, respectively).

Results

Median age at diagnosis was 61 (range 46–65) years; 131 (98%) were diagnosed with local disease. The median follow‐up time from diagnosis was 14 (range

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExomeProstatic NeoplasmsMaleHumansMiddle AgedAgedExome SequencingRetrospective StudiesGenetic Predisposition to DiseaseGerm-Line MutationGenomics

Stichwörter der Autor:innen

BRCAbiobankcancer susceptibility genesgermlineprostate cancerwhole exome sequencing

Autor:innen und Institutionen

  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Professional Medicine, Maccabi Healthcare Services, Tel Aviv, Israel.
  • KSM Research and Innovation Center, Maccabi Healthcare Services, Tel Aviv, Israel.
  • Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
  • BioInsight Ltd., Binyamina, Israel.
  • Genetic Institute, Maccabi Healthcare Services, Rehovot, Israel.

ORCID-Profile: Nava Siegelmann-Danieli

Förderung

  • KSM Maccabi Healthcare Services

Zitieren

APA

Siegelmann-Danieli, N., Neiman, V., Bareket-Samish, A., Berger, R., Peretz, A., Alapi, H., Tsur, E., Patalon, T., Beller, D., Rimler, G., Chodick, G., & Shohat, M. (2024). Whole exome germline sequencing in early‐onset prostate cancer patients: Genomic findings and clinical outcomes. The Prostate. https://doi.org/10.1002/pros.24622

Vancouver

Siegelmann-Danieli N, Neiman V, Bareket-Samish A, Berger R, Peretz A, Alapi H, et al. Whole exome germline sequencing in early‐onset prostate cancer patients: Genomic findings and clinical outcomes. The Prostate. 2024. doi:10.1002/pros.24622

BibTeX
@article{SiegelmannDanieli2024,
  author = {Siegelmann-Danieli, Nava and Neiman, Victoria and Bareket-Samish, Avital and Berger, Racheli and Peretz, Asaf and Alapi, Hillel and Tsur, Erez and Patalon, Tal and Beller, Daniella and Rimler, Galit and Chodick, Gabriel and Shohat, Mordechai},
  title = {Whole exome germline sequencing in early‐onset prostate cancer patients: Genomic findings and clinical outcomes},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24622}
}
Kostenlos starten →